GB982150A - Therapeutic resin complexes - Google Patents

Therapeutic resin complexes

Info

Publication number
GB982150A
GB982150A GB35268/61A GB3526861A GB982150A GB 982150 A GB982150 A GB 982150A GB 35268/61 A GB35268/61 A GB 35268/61A GB 3526861 A GB3526861 A GB 3526861A GB 982150 A GB982150 A GB 982150A
Authority
GB
United Kingdom
Prior art keywords
cross
linked
salt
resin
emetine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB35268/61A
Inventor
Wilfrid Herbert Linnell
John Harold Chapman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to GB35268/61A priority Critical patent/GB982150A/en
Priority to BE622943A priority patent/BE622943A/en
Priority to FR910733A priority patent/FR2489M/en
Publication of GB982150A publication Critical patent/GB982150A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/04—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine
    • C07D455/06—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine containing benzo [a] quinolizine ring systems
    • C07D455/08—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine containing benzo [a] quinolizine ring systems having an isoquinolyl-1, a substituted isoquinolyl-1 or an alkylenedioxyisoquinolyl-1 radical linked through only one carbon atom, attached in position 2, e.g. emetine
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F8/00—Chemical modification by after-treatment
    • C08F8/26—Removing halogen atoms or halogen-containing groups from the molecule
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Resinates for use in pharmaceutical compositions effective in the treatment of amoebic dysentery are prepared from l-emetine, l-2-de-hydroemetine, or a racemate, an active derivative or a salt thereof and a cross-linked cation-exchange resin in the hydrogen or salt form, said resin containing sulphonyl groups and being from 1 to 20% cross-linked. Specified resins are polystyrene cross-linked with divinyl benzene and containing sulphonic acid groups. Specification 977,789 is referred to.ALSO:Pharmaceutical compositions effective in the treatment of amoebic dysentery comprise a pharmaceutical carrier or excipient and a resinate formed from l-emetine, l-2-dehydroemetine or a racemate, an active derivative or a salt thereof, and a cross-linked cation exchange resin containing sulphonyl groups, said resin being from 1 to 20% cross-linked. The resin may be a sulphonated cross-linked polystyrene. The composition may be in the form of a powder, granulate, or an aqueous or oily suspension which may contain wetting-, suspending- or dispersing-agentswith/without flavouring or sweetening agents, or it may be in the form of a tablet or capsule. Specifications 977,788 and 977,789 are referred to.
GB35268/61A 1961-09-29 1961-09-29 Therapeutic resin complexes Expired GB982150A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GB35268/61A GB982150A (en) 1961-09-29 1961-09-29 Therapeutic resin complexes
BE622943A BE622943A (en) 1961-09-29 1962-09-27 Therapeutic compositions, containing emetine derivatives.
FR910733A FR2489M (en) 1961-09-29 1962-09-28 Drug for the treatment of amoebic dysentery.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB35268/61A GB982150A (en) 1961-09-29 1961-09-29 Therapeutic resin complexes

Publications (1)

Publication Number Publication Date
GB982150A true GB982150A (en) 1965-02-03

Family

ID=10375806

Family Applications (1)

Application Number Title Priority Date Filing Date
GB35268/61A Expired GB982150A (en) 1961-09-29 1961-09-29 Therapeutic resin complexes

Country Status (3)

Country Link
BE (1) BE622943A (en)
FR (1) FR2489M (en)
GB (1) GB982150A (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2373288A1 (en) * 1976-11-26 1978-07-07 Pennwalt Corp LONG-RELEASE PHARMACEUTICAL PREPARATION
FR2413090A1 (en) * 1975-07-18 1979-07-27 Abbott Lab PHARMACEUTICAL PREPARATION BASED ON ERYTHROMYCIN ETHYLSUCCINATE AND ITS APPLICATION AGAINST INFECTIONS SENSITIVE TO ERYTHROMYCIN
EP0254811A2 (en) * 1986-07-30 1988-02-03 Fisons Corporation Coated ion exchange resins
EP0254822A2 (en) * 1986-07-30 1988-02-03 Fisons Corporation Polymer-treated ion exchange resins
US4859461A (en) * 1986-07-30 1989-08-22 Fisons Corporation Coatable ion exchange resins
US4859462A (en) * 1986-07-30 1989-08-22 Fisons Corporation Polymer-treated ion exchange resins
GB2225941A (en) * 1988-11-11 1990-06-20 Euro Celtique Sa Pharmaceutical ion-exchange resin granules preparation
WO2006081518A2 (en) * 2005-01-28 2006-08-03 Collegium Pharmaceutical, Inc. Non-ionic non-aqueous vehicles for topical and oral administration of carrier-complexed active agents

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2413090A1 (en) * 1975-07-18 1979-07-27 Abbott Lab PHARMACEUTICAL PREPARATION BASED ON ERYTHROMYCIN ETHYLSUCCINATE AND ITS APPLICATION AGAINST INFECTIONS SENSITIVE TO ERYTHROMYCIN
FR2373288A1 (en) * 1976-11-26 1978-07-07 Pennwalt Corp LONG-RELEASE PHARMACEUTICAL PREPARATION
EP0254811A2 (en) * 1986-07-30 1988-02-03 Fisons Corporation Coated ion exchange resins
EP0254822A2 (en) * 1986-07-30 1988-02-03 Fisons Corporation Polymer-treated ion exchange resins
EP0254822A3 (en) * 1986-07-30 1989-04-05 Fisons Corporation Polymer-treated ion exchange resins
EP0254811A3 (en) * 1986-07-30 1989-04-05 Pennwalt Corporation Coated ion exchange resins
US4859461A (en) * 1986-07-30 1989-08-22 Fisons Corporation Coatable ion exchange resins
US4859462A (en) * 1986-07-30 1989-08-22 Fisons Corporation Polymer-treated ion exchange resins
GB2225941A (en) * 1988-11-11 1990-06-20 Euro Celtique Sa Pharmaceutical ion-exchange resin granules preparation
GB2225941B (en) * 1988-11-11 1992-12-09 Euro Celtique Sa Pharmaceutical ion exchange resin composition
WO2006081518A2 (en) * 2005-01-28 2006-08-03 Collegium Pharmaceutical, Inc. Non-ionic non-aqueous vehicles for topical and oral administration of carrier-complexed active agents
WO2006081518A3 (en) * 2005-01-28 2006-11-23 Collegium Pharmaceutical Inc Non-ionic non-aqueous vehicles for topical and oral administration of carrier-complexed active agents

Also Published As

Publication number Publication date
FR2489M (en) 1964-04-27
BE622943A (en) 1963-01-16

Similar Documents

Publication Publication Date Title
ZA754167B (en) Sulphonic acid salts of s-adenosilmethionine, process for the preparation thereof and therapeutic compositions containing them
NO161674C (en) ANALOGY PROCEDURE TE FOR THE PREPARATION OF THERAPEUTIC ACTIVE 6-SUBSTITUTED-S-TRIAZOLO (3,4-A) -TTHALAZINE DERIVATIVES.
GB982150A (en) Therapeutic resin complexes
ZA796356B (en) New hydroxypropyl-triazole compounds, their production and their medicinal use
NO170315C (en) PROCEDURE FOR THE PREPARATION OF FREE-CURRENT, HOMOGENT IODOFOR-SUSTAINED SOW POWDER
IL39286A0 (en) Pharmaceutical compositions comprising a clear aqueous solution of a 1,3-bis(chromon-5-yloxy)-propan-2-ol derivative or a salt thereof
GR60385B (en) New propargyl-2-phenylamino-imidazolines-(2),salts thereof by addition of their acids,pharmaceutical mediums containing the above and process for their preparation
ES414425A1 (en) Process for coating finely divided medicaments
YU126573A (en) Process for preparing new mono - and siesters of 2,5-dihydroxy benzene sulfonic acid
GR61158B (en) N-tetrahydrofurfuryl-noroxymorphone,salts thereof by addition of acid,pharmaceutical mediums containing them and process for the preparation thereof
ES451880A1 (en) Toothpaste compostion
GB1076968A (en) Process for the preparation of dry, solid choline salicylate containing compositions
NO144110C (en) ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE 5: 6-BENZO-4-PYRON DERIVATIVES
NO142716C (en) PROCEDURE FOR AA RESTORING THE MECHANICAL PROPERTIES IN USED PARTS OF HARD, SPRAY, CASTED SUPPLEMENTS
GB942873A (en) Pharmaceutical compositions containing resin-drug adsorbates
EG12274A (en) Process for the preparation of anthelmintic preparations containing 4(4-nitroanilino)-phenylisothiocyanate
ES312173A1 (en) Procedure to prepare cosmetic formulations that have depigmenting activity. (Machine-translation by Google Translate, not legally binding)
JPS5536484A (en) Novel 1*44dihydropyridazinee33carboxylic acid derivative
GB829245A (en) Resin-drug compounds
GB838952A (en) Resin-drug compounds
ES268449A1 (en) Process for the preparation of a member of the group consisting of a salt of furaltadone acid pamoate and a hydrate of the same (Machine-translation by Google Translate, not legally binding)
GB1045969A (en) Sodium betaine aspartate
HU174754B (en) Process for producing 1,3-dihydro-spiro-bracket-isobenzo-furane-1,4-piperidine-bracket closed derivatives and pharmaceutical compositions containing them as active agents
BE591554A (en) Continuous electrolytic regeneration of ion exchange resins
AU281945B2 (en) Therapeutic composition containing dimethylamino-3, 5, 6-trimethyl-pyrazine or its salts and process for preparation ofthe active ingredient